Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 7 (2010), Issue 2 (February)

1. Results of a multi-institution deformable registration accuracy study (MIDRAS).
   Int J Radiat Oncol Biol Phys, 76(2): 583-96. [Abstract] [Full-text]
2. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices.
   Int J Radiat Oncol Biol Phys, 76(2): 615-23. [Abstract] [Full-text]
3. Postoperative radiotherapy in the management of resected non-small-cell lung carcinoma: 10 years' experience in a single institute.
   Int J Radiat Oncol Biol Phys, 76(2): 433-9. [Abstract] [Full-text]
4. Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis.
   J R Soc Med, 103(2): 60-6. [Abstract] [Full-text]
5. Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features.
   Cancer Genet Cytogenet, 197(1): 39-45. [Abstract] [Full-text]
6. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray.
   Cancer, 116(3): 676-85. [Abstract] [Full-text]
7. Advances in target therapy for lung cancer.
   Jpn J Clin Oncol, 40(2): 101-6. [Abstract] [Full-text]
8. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.
   Cancer, 116(3): 670-5. [Abstract] [Full-text]
9. Prognostic significance of grading in lung adenocarcinoma.
   Cancer, 116(3): 659-69. [Abstract] [Full-text]
10. Underutilization of radiotherapy for lung cancer in New South Wales, Australia.
    Cancer, 116(3): 686-94. [Abstract] [Full-text]
11. Detection of CEA mRNA, p53 and AE1/AE3 in haematoxylin-eosin-negative lymph nodes of early-stage non-small cell lung cancer may improve veracity of N staging and indicate prognosis.
    Jpn J Clin Oncol, 40(2): 146-52. [Abstract] [Full-text]
12. Autofluorescence imaging videobronchoscopy improves assessment of tumor margins and affects therapeutic strategy in central lung cancer.
    Jpn J Clin Oncol, 40(2): 139-45. [Abstract] [Full-text]
13. Therapeutic effect of linac-based stereotactic radiotherapy with a micro-multileaf collimator for the treatment of patients with brain metastases from lung cancer.
    Jpn J Clin Oncol, 40(2): 119-24. [Abstract] [Full-text]
14. Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer.
    Jpn J Clin Oncol, 40(2): 125-9. [Abstract] [Full-text]
15. Establishment of shared antigen reactive cytotoxic T lymphocyte using co-stimulatory molecule introduced autologous cancer cells.
    Exp Mol Pathol, 88(1): 128-32. [Abstract] [Full-text]
16. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells.
    Cancer Lett, 288(2): 156-61. [Abstract] [Full-text]
17. Positron-emission tomography for lung cancer in a tuberculosis-endemic region.
    Asian Cardiovasc Thorac Ann, 18(1): 33-8. [Abstract] [Full-text]
18. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients.
    J Clin Invest, 120(2): 521-32. [Abstract] [Full-text]
19. Randomized clinical trials with biomarkers: design issues.
    J Natl Cancer Inst, 102(3): 152-60. [Abstract] [Full-text]
20. Body mass index and smoking-related lung cancer risk in the Singapore Chinese Health Study.
    Br J Cancer, 102(3): 610-4. [Abstract] [Full-text]
21. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung.
    Br J Cancer, 102(3): 602-9. [Abstract] [Full-text]
22. Activation of corticotropin-releasing factor receptor 2 inhibits the growth of human small cell lung carcinoma cells.
    Cancer Invest, 28(2): 146-55. [Abstract] [Full-text]
23. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.
    Cancer Invest, 28(2): 208-15. [Abstract] [Full-text]
24. The role of prostacyclin in lung cancer.
    Transl Res, 155(2): 57-61. [Abstract] [Full-text]
25. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation.
    Cancer Cell, 17(1): 89-97. [Abstract] [Full-text]
26. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
    Cancer Cell, 17(1): 77-88. [Abstract] [Full-text]
27. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis.
    Oncogene, 29(5): 635-46. [Abstract] [Full-text]
28. Cytopathologic differential diagnosis of small cell carcinoma and poorly differentiated non-small cell carcinoma in bronchial lavage specimens using a regression analysis.
    APMIS, 118(2): 150-5. [Abstract] [Full-text]
29. Microenvironmental modulation of asymmetric cell division in human lung cancer cells.
    Proc Natl Acad Sci U S A, 107(5): 2195-200. [Abstract] [Full-text]
30. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).
    J Clin Oncol, 28(5): 753-60. [Abstract] [Full-text]
31. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    J Clin Oncol, 28(5): 744-52. [Abstract] [Full-text]
32. Age- and sex-specific genomic profiles in non-small cell lung cancer.
    JAMA, 303(6): 535-43. [Abstract] [Full-text]
33. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
    Toxicol Lett, 192(3): 408-18. [Abstract] [Full-text]
34. Expression of glutathione S-transferase M2 in stage I/II non-small cell lung cancer and alleviation of DNA damage exposure to benzo[a]pyrene.
    Toxicol Lett, 192(3): 316-23. [Abstract] [Full-text]
35. Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers.
    Int J Radiat Oncol Biol Phys, 76(3): 782-8. [Abstract] [Full-text]
36. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.
    Int J Radiat Oncol Biol Phys, 76(3): 802-8. [Abstract] [Full-text]
37. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.
    Int J Radiat Oncol Biol Phys, 76(3): 775-81. [Abstract] [Full-text]
38. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
    Int J Radiat Oncol Biol Phys, 76(3): 789-95. [Abstract] [Full-text]
39. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
    Int J Radiat Oncol Biol Phys, 76(3): 809-15. [Abstract] [Full-text]
40. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.
    Int J Radiat Oncol Biol Phys, 76(3): 796-801. [Abstract] [Full-text]

© 2004-2010 Lung Cancer Research Today. All Rights Reserved.